CTRP13与冠心病合并糖尿病相关性研究进展

doi:10.3969/j.issn.1004-583X.2021.07.017

摘要/Abstract

摘要：

心血管疾病及代谢性疾病是全球公共卫生系统的重大负担。补体C1q/肿瘤坏死因子相关蛋白13(CTRP13)是一种高度保守的新型脂肪因子。研究发现,CTRP13具有抗炎、抗动脉粥样硬化、胰岛素增敏、调节糖脂和能量代谢等多种生物学作用,与机体代谢紊乱性疾病呈负相关。目前认为,CTRP13主要通过抑制炎症反应、保护内皮功能和改善糖代谢在冠心病和2型糖尿病中发挥积极作用,但具体机制尚未完全阐明,且在糖尿病方面的研究结果存在争议。本文就CTRP13对冠心病、2型糖尿病及其共病的影响及内在机制进行综述,以便为后续研究和临床应用提供新的依据。

关键词: 冠状动脉疾病, 糖尿病, 肿瘤坏死因子类, 脂肪因子

中图分类号:

刘慧卿, 金凤表, 李青联, 高宇, 侯瑞田. CTRP13与冠心病合并糖尿病相关性研究进展[J]. 临床荟萃, 2021, 36(7): 655-658.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.07.017

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I7/655

参考文献 28

[1]	Godoy LC, Rao V, Farkouh ME. Coronary revascularization of patients with diabetes mellitus in the setting of acute coronary syndromes[J]. Circulation, 2019,140(15):1233-1235. doi: 10.1161/CIRCULATIONAHA.119.040683 URL
[2]	Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update:A report from the American Heart Association[J]. Circulation, 2018,137(12):e67-e492.
[3]	Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I[J]. Eur Heart J, 2013,34(31):2436-2443. doi: 10.1093/eurheartj/eht149 URL
[4]	Onat A, Dönmez I, Karadeniz Y, et al. Type-2 diabetes and coronary heart disease: Common physiopathology, viewed from autoimmunity[J]. Expert Rev Cardiovasc Ther, 2014,12(6):667-679. doi: 10.1586/14779072.2014.910114 URL
[5]	Wong GW, Wang J, Hug C, et al. A family of Acrp30/adiponectin structural and functional paralogs[J]. Proc Natl Acad Sci U S A, 2004,101:10302-10307. doi: 10.1073/pnas.0403760101 URL
[6]	Seldin MM, Tan SY, Wong GW. Metabolic function of the CTRP family of hormones[J]. Rev Endocr Metab Disord, 2014,15(2):111-123. doi: 10.1007/s11154-013-9255-7 URL
[7]	Wei Z, Peterson JM, Wong GW. Metabolic regulation by C1q/TNF-related protein-13 (CTRP13): Activation of AMP-activated protein kinase and suppression of fatty acid-induced JNK signaling[J]. J Biol Chem, 2011,286(18):15652-15665. doi: 10.1074/jbc.M110.201087 URL
[8]	Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, et al. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin[J]. FASEB J, 2009,23(1):241-258. doi: 10.1096/fsb2.v23.1 URL
[9]	Schäfflfler A, Buechler C. CTRP family:Linking immunity to metabolism[J]. Trends Endocrinol Metab, 2012,23(4):194-204. doi: 10.1016/j.tem.2011.12.003 URL
[10]	Byerly MS, Swanson R, Wei Z, et al. A central role for C1q/TNF-related protein 13(CTRP13) in modulating food intake and body weight[J]. PLoS One, 2013,8(4):e62862-e62869. doi: 10.1371/journal.pone.0062862 URL
[11]	An K, Starkweather A, Sturgill J, et al. Association of CTRP13 with liver enzymes and cognitive symptoms in nonalcoholic fatty liver disease[J]. Nurs Res, 2019,68(1):29-38. doi: 10.1097/NNR.0000000000000319 URL
[12]	Fadaei R, Moradi N, Baratchian M, et al. Association of C1q/TNF-related protein-3 (CTRP3) and CTRP13 serum levels with coronary artery disease in subjects with and without type 2 diabetes mellitus[J]. PLoS One, 2016,11(12):e0168773-e0168786. doi: 10.1371/journal.pone.0168773 URL
[13]	Wang C, Xu W, Liang M, et al. CTRP13 inhibits atherosclerosis via autophagy-lysosome-dependent degradation of CD36[J]. FASEB J, 2019,33(2):2290-2300. doi: 10.1096/fsb2.v33.2 URL
[14]	Zheng Q, Yuan Y, Yi W, et al. C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway[J]. Arterioscler Thromb Vasc Biol, 2011,31(11):2616-2623. doi: 10.1161/ATVBAHA.111.231050 URL
[15]	Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis[J]. Circ Res, 2016,118(4):653-667. doi: 10.1161/CIRCRESAHA.115.306256 pmid: 26892964
[16]	Volobueva A, Zhang DW, Grechko AV, et al. Foam cell formation and cholesterol trafficking and metabolism disturbances in atherosclerosis[J]. Cor Vasa, 2019,61(1):48-55. doi: 10.1016/j.crvasa.2018.06.006 URL
[17]	Ou H, Liu C, Feng W, et al. Role of AMPK in atherosclerosis via autophagy regulation[J]. Sci China Life Sci, 2018,61(10):1212-1221. doi: 10.1007/s11427-017-9240-2 URL
[18]	Afrookhteh A, Emamgholipour S, Alipoor B, et al. The circulating levels of complement-C1q/TNF-related protein 13 (CTRP13) in patients with type 2 diabetes and its association with insulin resistance[J]. Clin Lab, 2017,63(2):327-333. doi: 10.7754/Clin.Lab.2016.160609 pmid: 28182339
[19]	Shanaki M, Fadaei R, Nariman M, et al. The circulating CTRP13 in type 2 diabetes and non-alcoholic fatty liver patients[J]. PLoS One, 2016,11(12):e0168082-e0168092. doi: 10.1371/journal.pone.0168082 URL
[20]	Kobayashi J. Which is the best predictor for the development of atherosclerosis among circulating lipoprotein lipase, hepatic lipase, and endothelial lipase?[J]. J Atheroscler Thromb, 2019,26(9):758-759. doi: 10.5551/jat.ED108 pmid: 30814386
[21]	Radulovi'c S, Gottschalk B, Hörl G, et al. Endothelial lipase increases eNOS activating capacity of high-density lipoprotein[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020,1865(4):158612-158623.
[22]	Bai B, Ban B, Liu Z, et al. Circulating c1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in type 2 diabetes mellitus: In vivo regulation by glucose[J]. PLoS One, 2017,12(2):e0172271-e0172282. doi: 10.1371/journal.pone.0172271 URL
[23]	Strauss HW, Nakahara T, Narula N, et al. Vascular calcification:The evolving relationship of vascular calcification to major acute coronary events[J]. J Nucl Med, 2019,60(9):1207-1212. doi: 10.2967/jnumed.119.230276 URL
[24]	Li Y, Wang W, Chao Y, et al. CTRP13 attenuates vascular calcification by regulating Runx2[J]. FASEB J, 2019,33(8):9627-9637. doi: 10.1096/fsb2.v33.8 URL
[25]	Shanaki M, Moradi N, Fadaei R, et al. Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: Irrespective of obesity[J]. PLoS One, 2018,13(12):e0208059-e0208070. doi: 10.1371/journal.pone.0208059 URL
[26]	Koh KK. Role of adiponectin: important or null?[J]. J Am Coll Cardiol, 2017,69(11):1518-1524.
[27]	Xu W, Tian M, Zhou Y. The relationship between insulin resistance, adiponectin and C-reactive protein and vascular endothelial injury in diabetic patients with coronary heart disease[J]. Exp Ther Med, 2018,16(3):2022-2026.
[28]	Wang C, Chao Y, Xu W, et al. CTRP13 preserves endothelial function by targeting GTP cyclohydrolase 1 in diabetes[J]. Diabetes, 2020,69(1):99-111. doi: 10.2337/db19-0635 URL

CTRP13与冠心病合并糖尿病相关性研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄宇玲, 张欣悦, 荣萍萍, 杨文琦, 曹新营, 邢彩耐, 王志军, 刘宁. Non-HDL-C/HDL-C和NHR与冠状动脉病变严重程度的相关性[J]. 临床荟萃, 2024, 39(2): 115-120.
[2]	吕莎莎, 宋金兰, 石健. m.3243A>G突变相关线粒体糖尿病1例并文献复习[J]. 临床荟萃, 2024, 39(2): 160-163.
[3]	张佳楠, 孙琳琳, 詹潇燕, 李冰. 血清维生素B₁₂与老年2型糖尿病轻度认知功能障碍的关系[J]. 临床荟萃, 2024, 39(1): 34-37.
[4]	李华, 陈建军, 未纪涛, 张旗. 血清胱抑素C水平与非阻塞性冠状动脉疾病的关系[J]. 临床荟萃, 2023, 38(9): 802-805.
[5]	位增, 曹灵, 佘敦敏, 刘彦, 王艳, 张真稳. 54例2型糖尿病患者合并新型冠状病毒感染的死亡原因分析[J]. 临床荟萃, 2023, 38(9): 806-812.
[6]	张娜文, 黄少敏, 田利民. 2型糖尿病与帕金森病相关性研究的进展[J]. 临床荟萃, 2023, 38(9): 845-850.
[7]	杨鑫, 许华娇. 基于Web of Science糖尿病患者心理干预研究的文献计量学分析[J]. 临床荟萃, 2023, 38(8): 731-736.
[8]	马光宇, 罗慧娟, 王冬菊, 肖小敏. 黄芩苷治疗糖尿病及其并发症的研究进展[J]. 临床荟萃, 2023, 38(8): 757-762.
[9]	张欣欣, 刘国庆, 王蓓蓓. 糖尿病酮症酸中毒引起极度血小板增多症1例并文献复习[J]. 临床荟萃, 2023, 38(8): 719-721.
[10]	金家辉, 杨阳, 秦铜, 何雨欣, 苏美华. 补充益生菌对2型糖尿病患者糖代谢改善的meta分析[J]. 临床荟萃, 2023, 38(7): 581-587.
[11]	贾丽娜, 吴美妮, 尹昌浩. 2型糖尿病认知功能障碍发病机制的研究进展[J]. 临床荟萃, 2023, 38(6): 554-558.
[12]	陈婷, 刘金彦. 中药靶向PI3K/Akt/mTOR通路调节自噬在糖尿病肾脏病中的研究进展[J]. 临床荟萃, 2023, 38(6): 564-568.
[13]	苏晨蓓, 王富军. 糖尿病下肢动脉疾病介入治疗疗效的研究进展[J]. 临床荟萃, 2023, 38(6): 569-572.
[14]	吴亚楠, 延天美, 梁鹏, 魏立民. 中老年糖尿病患者抑郁症状的高危识别[J]. 临床荟萃, 2023, 38(6): 516-520.
[15]	吕丽丽, 翟满满, 丁小艳, 陈永清. 线粒体转录因子A介导的线粒体功能障碍在糖尿病心肌病中的作用[J]. 临床荟萃, 2023, 38(5): 465-468.